These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36609928)

  • 1. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
    Nakamura A; Hashimoto M; Kondo N; Matsumoto S; Kuroda A; Minami T; Kitajima K; Kuribayashi K; Kijima T; Hasegawa S
    Int J Clin Oncol; 2023 Mar; 28(3):409-415. PubMed ID: 36609928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
    Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
    Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
    Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
    Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
    Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
    Bylicki O; Guisier F; Scherpereel A; Daniel C; Swalduz A; Grolleau E; Bernardi M; Hominal S; Prevost JB; Pamart G; Marques MH; Cloarec N; Deshayes S; Raimbourg J; Veillon R; Oulkhouir Y; Audigier Valette C; Subtil F; Chouaïd C; Greillier L;
    Lung Cancer; 2024 Aug; 194():107866. PubMed ID: 38972083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    Schadendorf D; Wolchok JD; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Chesney J; Robert C; Grossmann K; McDermott D; Walker D; Bhore R; Larkin J; Postow MA
    J Clin Oncol; 2017 Dec; 35(34):3807-3814. PubMed ID: 28841387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
    J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Wright K
    Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
    Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
    Front Public Health; 2022; 10():947375. PubMed ID: 35937220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.